Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology

Read also

Merck KGaA

Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

FDA Approves Perioperative Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible MIBC

ALS oral therapy

ALS oral therapy slows disease progression in preclinical testing

Alvotech and Advanz

Alvotech and Advanz announce EC approval for Gobivaz biosimilar